Status:
NOT_YET_RECRUITING
Oral Carnitine in Heart Failure Patients
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
Heart Failure
Carnitine Deficiency
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally ...
Detailed Description
Heart failure (HF) is a multi-organ syndrome that is fundamentally driven by metabolic failure. Metabolic alterations include reduced fatty acid oxidation, which is the main fuel source for cardiac my...
Eligibility Criteria
Inclusion
- Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome
- Stage 1, 2, 3a, 3b, or 4 chronic kidney disease
- Age ≥ 18 years
- Able to speak and read English
- Willing and able to provide consent
Exclusion
- Estimated GFR \<15 mL/min/1.73m2 or Stage 5 chronic kidney disease
- Currently undergoing renal replacement therapy of any kind
- Pregnant, breastfeeding or intending pregnancy
- History of seizures of any type
- Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone
- Unable to provide consent
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07201714
Start Date
December 1 2025
End Date
December 31 2026
Last Update
October 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London Health Sciences Centre
London, Ontario, Canada, N6A 5W9